Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sarink, DanjaSchock, Helena
Johnson, Theron
Overvad, Kim
Holm, Marianne
Tjønneland, Anne
Boutron-Ruault, Marie-Christine
His, Mathilde
Kvaskoff, Marina
Boeing, Heiner
Lagiou, Pagona
Papatesta, Eleni-Maria
Trichopoulou, Antonia
Palli, Domenico
Pala, Valeria
Mattiello, Amalia
Tumino, Rosario
Sacerdote, Carlotta
Bueno-de-Mesquita, H B As
van Gils, Carla H
Peeters, Petra H
Weiderpass, Elisabete
Agudo, Antonio
Sánchez, Maria-José
Chirlaque, Maria-Dolores
Ardanaz, Eva
Amiano, Pilar
Khaw, Kay Tee
Travis, Ruth
Dossus, Laure
Gunter, Mark
Rinaldi, Sabina
Merritt, Melissa
Riboli, Elio
Kaaks, Rudolf
Fortner, Renée T
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.Published in
Cancer Prev Res 2017; 10(9):525-34Publiekssamenvatting
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary tumor development in experimental models. Circulating concentrations of soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and breast cancer risk by hormone receptor subtype has not previously been investigated. A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. This study included 1,976 incident invasive breast cancer cases [estrogen receptor positive (ER+),n= 1,598], matched 1:1 to controls. Women were pre- or postmenopausal at blood collection. Serum sRANKL was quantified using an ELISA, serum OPG using an electrochemiluminescent assay. Risk ratios (RR) and 95% confidence intervals (95% CI) were calculated using conditional logistic regression. Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status (Phet= 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast cancer [5th vs. 1st quintile RR 1.28 (95% CI, 1.01-1.63);Ptrend= 0.20], but not ER- disease. For both ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse association between the ratio and ER-PR- disease [5th vs. 1st quintile RR = 0.60 (0.31-1.14);Ptrend= 0.03]. This study provides the first large-scale prospective data on circulating sRANKL and breast cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.Cancer Prev Res; 10(9); 525-34. ©2017 AACR.PMID
28701332ae974a485f413a2113503eed53cd6c53
10.1158/1940-6207.CAPR-17-0125
Scopus Count
Collections
Related articles
- Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
- Authors: Sarink D, Schock H, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tjønneland A, Arveux P, Fournier A, Kvaskoff M, Boeing H, Karakatsani A, Trichopoulou A, La Vecchia C, Masala G, Agnoli C, Panico S, Tumino R, Sacerdote C, van Gils CH, Peeters PHM, Weiderpass E, Agudo A, Rodríguez-Barranco M, Huerta JM, Ardanaz E, Gil L, Kaw KT, Schmidt JA, Dossus L, His M, Aune D, Riboli E, Kaaks R, Fortner RT
- Issue date: 2018 Oct 22
- Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
- Authors: Fortner RT, Sarink D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Affret A, His M, Boutron-Ruault MC, Boeing H, Trichopoulou A, Naska A, Orfanos P, Palli D, Sieri S, Mattiello A, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Peeters PH, Van Gils CH, Weiderpass E, Lund E, Quirós JR, Agudo A, Sánchez MJ, Chirlaque MD, Ardanaz E, Dorronsoro M, Key T, Khaw KT, Rinaldi S, Dossus L, Gunter M, Merritt MA, Riboli E, Kaaks R
- Issue date: 2017 Feb 8
- Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort.
- Authors: Sarink D, Yang J, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tjønneland A, Fournier A, Mancini FR, Kvaskoff M, Boeing H, Trichopoulou A, Karakatsani A, Valanou E, Agnoli C, Sacerdote C, Masala G, Mattiello A, Tumino R, Van Gils CH, Skeie G, Gram IT, Weiderpass E, Lujan-Barroso L, Petrova D, Santiuste C, Quirós JR, Barricarte A, Amiano P, Travis RC, Gunter M, Dossus L, Christakoudi S, Kaaks R, Fortner RT
- Issue date: 2019 Oct
- OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.
- Authors: LaCroix AZ, Jackson RD, Aragaki A, Kooperberg C, Cauley JA, Chen Z, Leboff MS, Duggan D, Wactawski-Wende J
- Issue date: 2013 Oct
- Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
- Authors: Todenhöfer T, Hennenlotter J, Leidenberger P, Wald A, Hohneder A, Kühs U, Mischinger J, Aufderklamm S, Gakis G, Blumenstock G, Stenzl A, Schwentner C
- Issue date: 2014 Jan